RSS Feeds
Search

Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

No results found for given criteria.

Related Reports

Market Research Reports provided by reports.iptechex.com
Vertex’s VX770 Is Poised To Become The First Targeted Therapy To Be Approved In Cystic Fibrosis
Mar 2011 - 4 pages - $500
Personalized Medicine Partnering Terms and Agreements
Apr 2011 - 951 pages - $4,995
Cystic Fibrosis Therapy Area Pipeline Report
Nov 2010 - 176 pages - $1,495
Pulmonary Fibrosis Therapy Area Pipeline Report
Nov 2010 - 115 pages - $1,495
Pulmonary Fibrosis Global Clinical Trials Review, Q4, 2010
Dec 2010 - 52 pages - $1,000
Liver Fibrosis Global Clinical Trials Review, Q1, 2011
Apr 2011 - 57 pages - $1,000
Delay in Phase-out Plan Will Benefit the German Nuclear Industry
Oct 2009 - 13 pages - $500
Cystic Fibrosis - Pipeline Review, Q1 2011
Feb 2011 - 84 pages - $500
Marien-Hospital Wesel GmbH - Strategic SWOT Analysis Review
May 2011 - 15 pages - $250
Englewood Hospital and Medical Center - Strategic SWOT Analysis Review
May 2011 - 15 pages - $250
More Related Market Research Reports >>>

Your selection

Industry sector
Diagnostic del
Nuclear medicine del
Therapeutic target
Hospital and Surgery del
Fibrosis del
Development phase
Phase III/IV del

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us